摘要
目的观察恩替卡韦(ETV)对慢性乙型肝炎肝纤维化患者血清TGF-β1、肝纤维化指标及肝组织病理的影响。方法采用ELISA法检测32例慢性乙型肝炎肝纤维化患者治疗前、治疗48周后血清TGF-β1的水平;治疗前后血清肝纤维化指标透明质酸(HA)、Ⅳ型胶原(CⅣ)、Ⅲ型前胶原肽(PⅢP)、层粘连蛋白(LN)采用放射免疫法;并对32例患者治疗前后进行肝脏穿刺活检常规病理染色。结果治疗48周后,血清TGF-β1水平较治疗前明显降低,差异有统计学意义(P<0.05);血清肝纤维化指标HA、CⅣ、PⅢP、LN较治疗前明显降低,差异有统计学意义(P<0.05);治疗后肝组织炎症分级、纤维化分期较治疗前明显改善,差异均有统计学意义(P<0.05)。结论恩替卡韦可通过下调血清细胞因子TGF-β1的表达水平,从而改善慢性乙型肝炎患者肝纤维化程度。
Objective To observe the changes of serum TGF-β1 , liver fibrosis indexes levels and liver pathology with Entecavir （ETV） on patients with hepatic fibrosis of chronic hepatitis B. Methods A total of 32 patients with hepatic fibrosis of chronic hepatitis B were enrolled and treated with Entecavir for 48 weeks. Before and 48 weeks after treatment, the serum level of TGF-β1 was assessed by EL1SA, the levels of related liver fibrosis indexes were measured by RIA, and the liver tissue was dyed with HE dyeing, Masson dyeing. Results After 48 weeks treatment with ETV, the level of serum TGF-β1 was decreased significantly compared with those before （P〈0.05）. Also, the serum liver fibrosis indexes were significantly reduced （P〈 0.05）. Liver pathology was improved after 48 week ETV treatment both in inflammation grading and fibrosis degree, the differences were significant （P〈0. 05）. Conclusion Entecavir may improve the degree of liver fibrosis in patients with chronic hepatitis B by lowering expression of serum eytokine TGF-β1.
出处
《福建医药杂志》
CAS
2015年第3期87-89,F0003,共4页
Fujian Medical Journal
